评估血浆生物标志物预测COVID-19住院患者主要不良肾脏事件
这项前瞻性队列研究纳入3个学术医疗中心2020年3月至2021年1月期间576例COVID-19住院患者,检测26种血浆生物标志物。95例(16%)发生主要不良肾脏事件(MAKE)。sTNFR1和sTNFR2每升高1个标准差与MAKE风险独立相关,AHR分别为2.30和2.26,单独预测C指数分别为0.80和0.81;LASSO和随机森林模型C指数分别为0.86和0.84。
要点
- COVID-19住院患者中16%发生MAKE,中位住院9天。
- sTNFR1每升高1个标准差,MAKE风险AHR为2.30。
- sTNFR2每升高1个标准差,MAKE风险AHR为2.26。
核心结论
- sTNFR1和sTNFR2与COVID-19住院患者MAKE独立相关,且均可作为不良肾脏结局的预测指标。
研究设计与样本
- 前瞻性队列研究,纳入3个学术医疗中心2020年3月至2021年1月期间576例COVID-19住院患者。
主要发现
- 95例患者(16%)发生MAKE,中位住院时间为9天(IQR 5-16天)。
- sTNFR1每升高1个标准差与MAKE风险增加相关,AHR为2.30(95% CI 1.86-2.85)。
- sTNFR2每升高1个标准差与MAKE风险增加相关,AHR为2.26(95% CI 1.73-2.95)。
- sTNFR1单独预测MAKE的C指数为0.80(95% CI 0.78-0.84),sTNFR2为0.81(95% CI 0.77-0.84)。
- 使用全部生物标志物的LASSO和随机森林回归模型C指数分别为0.86(95% CI 0.83-0.89)和0.84(95% CI 0.78-0.91)。
关键数值与推荐
- MAKE定义为KDIGO 3期急性肾损伤、需要透析的急性肾损伤或60天内死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无COVID-19以外的住院患者对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Patients hospitalized with COVID-19 are at increased risk for major adverse kidney events (MAKE). We sought to identify plasma biomarkers predictive of MAKE in patients hospitalized with COVID-19. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: A total of 576 patients hospitalized with COVID-19 between March 2020 and January 2021 across 3 academic medical centers. EXPOSURE: Twenty-six plasma biomarkers of injury, inflammation, and repair from first available blood samples collected during hospitalization. OUTCOME: MAKE, defined as KDIGO stage 3 acute kidney injury (AKI), dialysis-requiring AKI, or mortality up to 60 days. ANALYTICAL APPROACH: Cox proportional hazards regression to associate biomarker level with MAKE. We additionally applied the least absolute shrinkage and selection operator (LASSO) and random forest regression for prediction modeling and estimated model discrimination with time-varying C index. RESULTS: The median length of stay for COVID-19 hospitalization was 9 (IQR, 5-16) days. In total, 95 patients (16%) experienced MAKE. Each 1 SD increase in soluble tumor necrosis factor receptor 1 (sTNFR1) and sTNFR2 was significantly associated with an increased risk of MAKE (adjusted HR [AHR], 2.30 [95% CI, 1.86-2.85], and AHR, 2.26 [95% CI, 1.73-2.95], respectively). The C index of sTNFR1 alone was 0.80 (95% CI, 0.78-0.84), and the C index of sTNFR2 was 0.81 (95% CI, 0.77-0.84). LASSO and random forest regression modeling using all biomarkers yielded C indexes of 0.86 (95% CI, 0.83-0.89) and 0.84 (95% CI, 0.78-0.91), respectively. LIMITATIONS: No control group of hospitalized patients without COVID-19. CONCLUSIONS: We found that sTNFR1 and sTNFR2 are independently associated with MAKE in patients hospitalized with COVID-19 and can both also serve as predictors for adverse kidney outcomes. PLAIN-LANGUAGE SUMMARY: Patients hospitalized with COVID-19 are at increased risk for long-term adverse health outcomes, but not all patients suffer long-term kidney dysfunction. Identification of patients with COVID-19 who are at high risk for adverse kidney events may have important implications in terms of nephrology follow-up and patient counseling. In this study, we found that the plasma biomarkers soluble tumor necrosis factor receptor 1 (sTNFR1) and sTNFR2 measured in hospitalized patients with COVID-19 were associated with a greater risk of adverse kidney outcomes. Along with clinical variables previously shown to predict adverse kidney events in patients with COVID-19, both sTNFR1 and sTNFR2 are also strong predictors of adverse kidney outcomes.
引用
- Menez S, Coca SG, Moledina DG, et al. Evaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19. Am J Kidney Dis. 2023. PMID: 37263570. doi:10.1053/j.ajkd.2023.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。